We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-20.78%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$664M
AUM Growth
-$172M
Cap. Flow
+$85.8M
Cap. Flow %
12.92%
Top 10 Hldgs %
40.96%
Holding
86
New
4
Increased
14
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$22.2M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$17.1M
3
NKTR icon
Nektar Therapeutics
NKTR
+$15.8M
4
KA
Kineta, Inc. Common Stock
KA
+$13.6M
5
NVRO
NEVRO CORP.
NVRO
+$13M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$52.7M
2
BPMC
Blueprint Medicines
BPMC
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 86.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$32.9B
$10.4M 1.57%
612,000
– –
CELG
27
DELISTED
Celgene Corp
CELG
$10M 1.51%
+100,000
New +$10.3M
RMTI icon
28
Rockwell Medical
RMTI
$28.5M
$8.3M 1.25%
10,045
– –
NVAX icon
29
Novavax
NVAX
$1.22B
$8.26M 1.24%
80,000
– –
COLL icon
30
Collegium Pharmaceutical
COLL
$1.15B
$8.17M 1.23%
450,000
– –
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.07M 1.22%
753,388
– –
ADXS
32
DELISTED
Advaxis Inc
ADXS
$7.22M 1.09%
53,333
– –
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$2.46B
$6.93M 1.04%
109,500
– –
CPXX
34
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$6.84M 1.03%
+620,000
New +$2.03M
LPCN icon
35
Lipocine
LPCN
$17.4M
$6.77M 1.02%
39,216
– –
MCRB icon
36
Seres Therapeutics
MCRB
$48.7M
$6.64M 1%
12,500
– –
AGEN
37
Agenus
AGEN
$326M
$6.49M 0.98%
79,431
– –
PFNX
38
DELISTED
Pfenex Inc.
PFNX
$6.14M 0.93%
624,900
– –
FWP
39
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$5.7M 0.86%
47,867
– –
WVE icon
40
Wave Life Sciences
WVE
$1.13B
$5.44M 0.82%
392,079
– –
XLRN
41
DELISTED
Acceleron Pharma
XLRN
$5.28M 0.8%
200,000
– –
CTMX icon
42
CytomX Therapeutics
CTMX
$690M
$4.79M 0.72%
371,023
– –
SCTL
43
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.66M 0.7%
869,700
– –
ZYNE
44
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$4.49M 0.68%
475,035
+118,435
+33% +$955K
ACHN
45
DELISTED
Achillion Pharmaceuticals
ACHN
$3.86M 0.58%
500,000
– –
DERM
46
DELISTED
Dermira, Inc.
DERM
$3.52M 0.53%
170,000
– –
AGRX
47
DELISTED
Agile Therapeutics
AGRX
$3.46M 0.52%
279
+188
+207% +$2.43M
CYAD
48
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$3.31M 0.5%
75,000
– –
INDP icon
49
Indaptus Therapeutics
INDP
$175M
$3.3M 0.5%
357
– –
EPZM
50
DELISTED
Epizyme, Inc
EPZM
$3.23M 0.49%
266,250
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cormorant Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Cormorant Asset Management held 86 positions worth $664M, down 21% from $836M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management deployed $85.8M of net new capital in Q1 2016, opening 4 new positions and adding to 14 existing holdings. Its largest new stake was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier.

On the sell side, the most notable exit was DYAX CORPORATION, an estimated $52.7M sold.

  • Cormorant Asset Management's largest Q1 2016 buy was Kineta, Inc. Common Stock: 12,333 shares worth $16.6M.
  • Cormorant Asset Management added most to Sage Therapeutics in Q1 2016, an estimated $22.2M increase.
  • Cormorant Asset Management fully exited DYAX CORPORATION in Q1 2016, selling an estimated $52.7M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $664M portfolio in Q1 2016.
  • Cormorant Asset Management opened 4 new positions and closed 2 in Q1 2016.
  • Cormorant Asset Management's portfolio value fell 21% quarter-over-quarter to $664M.

Based on Cormorant Asset Management's 13F filing for Q1 2016, filed 16 May 2016.